S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:OPTN

OptiNose Competitors

$3.88
-0.14 (-3.48 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.87
Now: $3.88
$4.11
50-Day Range
$3.98
MA: $4.29
$4.75
52-Week Range
$3.14
Now: $3.88
$10.00
Volume512,426 shs
Average Volume445,312 shs
Market Capitalization$202.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03

Competitors

OptiNose (NASDAQ:OPTN) Vs. KDMN, ANAB, ESPR, PRVB, ICPT, and GOSS

Should you be buying OPTN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to OptiNose, including Kadmon (KDMN), AnaptysBio (ANAB), Esperion Therapeutics (ESPR), Provention Bio (PRVB), Intercept Pharmaceuticals (ICPT), and Gossamer Bio (GOSS).

Kadmon (NASDAQ:KDMN) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Volatility and Risk

Kadmon has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, OptiNose has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Valuation and Earnings

This table compares Kadmon and OptiNose's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kadmon$5.09 million154.66$-61,370,000.00($0.74)-6.20
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48

Kadmon has higher earnings, but lower revenue than OptiNose. Kadmon is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Kadmon and OptiNose, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kadmon00503.00
OptiNose01202.67

Kadmon presently has a consensus target price of $14.00, suggesting a potential upside of 205.01%. OptiNose has a consensus target price of $19.00, suggesting a potential upside of 389.69%. Given OptiNose's higher possible upside, analysts clearly believe OptiNose is more favorable than Kadmon.

Institutional & Insider Ownership

94.8% of Kadmon shares are owned by institutional investors. Comparatively, 62.9% of OptiNose shares are owned by institutional investors. 3.0% of Kadmon shares are owned by company insiders. Comparatively, 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Kadmon and OptiNose's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kadmon-768.36%-85.07%-46.46%
OptiNose-230.14%-294.64%-59.29%

Summary

Kadmon beats OptiNose on 9 of the 14 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Analyst Ratings

This is a breakdown of current recommendations for AnaptysBio and OptiNose, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio03302.50
OptiNose01202.67

AnaptysBio presently has a consensus target price of $26.4286, suggesting a potential downside of 7.91%. OptiNose has a consensus target price of $19.00, suggesting a potential upside of 389.69%. Given OptiNose's stronger consensus rating and higher possible upside, analysts clearly believe OptiNose is more favorable than AnaptysBio.

Volatility and Risk

AnaptysBio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, OptiNose has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Institutional & Insider Ownership

62.9% of OptiNose shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares AnaptysBio and OptiNose's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
OptiNose-230.14%-294.64%-59.29%

Valuation and Earnings

This table compares AnaptysBio and OptiNose's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million98.11$-97,340,000.00($3.60)-7.97
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48

AnaptysBio has higher earnings, but lower revenue than OptiNose. AnaptysBio is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats AnaptysBio on 8 of the 14 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Esperion Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptiNose01202.67
Esperion Therapeutics23312.33

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Esperion Therapeutics has a consensus price target of $52.8889, suggesting a potential upside of 93.10%. Given OptiNose's stronger consensus rating and higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Esperion Therapeutics.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 7.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptiNose-230.14%-294.64%-59.29%
Esperion Therapeutics-46.15%-629.88%-41.43%

Earnings and Valuation

This table compares OptiNose and Esperion Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48
Esperion Therapeutics$148.36 million5.15$-97,170,000.00($3.59)-7.63

Esperion Therapeutics has higher revenue and earnings than OptiNose. Esperion Therapeutics is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats Esperion Therapeutics on 8 of the 15 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Provention Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptiNose01202.67
Provention Bio00403.00

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Provention Bio has a consensus price target of $30.75, suggesting a potential upside of 141.75%. Given OptiNose's higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Provention Bio.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. Comparatively, 39.4% of Provention Bio shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 14.4% of Provention Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Provention Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptiNose-230.14%-294.64%-59.29%
Provention BioN/A-67.66%-62.27%

Earnings and Valuation

This table compares OptiNose and Provention Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48
Provention BioN/AN/A$-43,280,000.00($1.06)-12.00

Provention Bio has lower revenue, but higher earnings than OptiNose. Provention Bio is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

Provention Bio beats OptiNose on 7 of the 13 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Intercept Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptiNose01202.67
Intercept Pharmaceuticals214802.25

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Intercept Pharmaceuticals has a consensus price target of $55.4783, suggesting a potential upside of 156.13%. Given OptiNose's stronger consensus rating and higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Intercept Pharmaceuticals.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptiNose-230.14%-294.64%-59.29%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Earnings and Valuation

This table compares OptiNose and Intercept Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48
Intercept Pharmaceuticals$252 million2.84$-344,680,000.00($10.89)-1.99

OptiNose has higher earnings, but lower revenue than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats Intercept Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Gossamer Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptiNose01202.67
Gossamer Bio00503.00

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Gossamer Bio has a consensus price target of $22.80, suggesting a potential upside of 142.55%. Given OptiNose's higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Gossamer Bio.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptiNose-230.14%-294.64%-59.29%
Gossamer BioN/A-64.34%-46.52%

Earnings and Valuation

This table compares OptiNose and Gossamer Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptiNose$34.63 million5.84$-110,050,000.00($2.63)-1.48
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.86

OptiNose has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

Gossamer Bio beats OptiNose on 7 of the 13 factors compared between the two stocks.


OptiNose Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kadmon logo
KDMN
Kadmon
2.0$4.59-0.2%$787.25 million$5.09 million-7.65Upcoming Earnings
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.1$28.70-9.5%$784.89 million$8 million-10.59Earnings Announcement
Insider Buying
Analyst Revision
News Coverage
Gap Up
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.39-1.1%$763.55 million$148.36 million-7.11Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Provention Bio logo
PRVB
Provention Bio
1.4$12.72-0.9%$718.53 millionN/A-8.54Earnings Announcement
Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.66-6.4%$714.61 million$252 million-2.21Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.40-4.1%$713.72 millionN/A-2.64Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.4$22.50-8.9%$711.07 million$31.13 million-7.33Gap Up
OrganiGram logo
OGI
OrganiGram
1.2$3.03-1.7%$703.78 million$64.61 million-4.46Unusual Options Activity
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.15-0.2%$701.27 million$59.29 million-27.66Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Akouos logo
AKUS
Akouos
1.7$20.37-2.1%$700.38 millionN/A0.00Upcoming Earnings
High Trading Volume
News Coverage
Gap Down
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$16.54-1.7%$697.29 million$17.26 million-4.59
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$28.07-2.7%$672.81 million$19.56 million-20.19Analyst Report
Decrease in Short Interest
News Coverage
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$34.86-0.6%$665.02 million$9.64 million-5.68Earnings Announcement
Analyst Revision
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.4$18.68-3.0%$653.93 million$6.83 million-19.26Upcoming Earnings
Analyst Report
BCEL
Atreca
1.7$17.35-2.3%$636.87 millionN/A-6.15Earnings Announcement
News Coverage
Gap Down
Chimerix logo
CMRX
Chimerix
1.3$9.81-8.8%$614.44 million$12.52 million-17.21Earnings Announcement
News Coverage
Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$32.87-1.1%$589.75 million$12.69 million-15.80Analyst Report
Insider Selling
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$16.46-1.0%$589.50 millionN/A0.00Upcoming Earnings
Ardelyx logo
ARDX
Ardelyx
1.9$6.45-0.3%$582.10 million$5.28 million-6.39Upcoming Earnings
News Coverage
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$44.50-2.9%$579.84 million$195.89 million127.15Upcoming Earnings
Gap Down
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$12.17-12.2%$577.71 millionN/A-4.89Upcoming Earnings
Gap Down
IVA
Inventiva
0.0$15.00-3.6%$575.90 millionN/A0.00High Trading Volume
Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.77-3.0%$559.03 million$56.50 million0.00Decrease in Short Interest
Gap Down
XBiotech logo
XBIT
XBiotech
1.2$19.00-0.3%$555.96 millionN/A1.32
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
IDYA
IDEAYA Biosciences
1.3$19.07-4.7%$554.37 millionN/A-10.14Gap Up
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$21.72-5.6%$553.73 millionN/A-4.56Insider Buying
News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.14-2.1%$549.95 millionN/A-4.87Upcoming Earnings
News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.90-1.1%$544.61 million$22.27 million-5.34Analyst Upgrade
Insider Buying
News Coverage
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$7.59-0.9%$544.51 million$111.75 million-8.43
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.02-0.5%$543.45 million$72.96 million-3.57
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.34-1.5%$541.51 millionN/A-15.44Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$25.27-1.3%$538.38 million$13.80 million-12.21
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.17-0.1%$529.45 millionN/A-3.14
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Report
Analyst Revision
Altimmune logo
ALT
Altimmune
1.9$15.94-7.9%$527.15 million$5.80 million-8.01Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.74-2.2%$527.10 million$58.12 million-17.14Increase in Short Interest
News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.98-0.6%$508.06 millionN/A-6.36News Coverage
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.51-1.5%$507.69 millionN/A-5.39Upcoming Earnings
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-3.2%$504.90 million$25 million-18.52News Coverage
Gap Down
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.6$15.29-1.6%$503.38 million$1.19 million-6.37
Affimed logo
AFMD
Affimed
1.6$5.67-5.3%$500.81 million$23.96 million-9.61News Coverage
Gap Up
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43-5.0%$500.51 million$109.33 million-2.52News Coverage
Gap Down
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.46-0.3%$500.11 million$335 million-1.17Earnings Announcement
Analyst Revision
News Coverage
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.74-2.1%$499.66 millionN/A-13.76Analyst Upgrade
Analyst Revision
Gap Down
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$18.17-1.2%$493.99 million$18.15 million-4.28
SIGA
SIGA Technologies
0.3$6.32-0.9%$489.17 million$26.74 million15.80Upcoming Earnings
News Coverage
89bio logo
ETNB
89bio
1.6$24.56-1.3%$488.23 millionN/A-4.86
Homology Medicines logo
FIXX
Homology Medicines
1.7$10.74-0.9%$486.14 million$1.67 million-3.93High Trading Volume
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.5$20.90-1.5%$485.17 millionN/A0.00Upcoming Earnings
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.